Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gilead Sciences
(NQ:
GILD
)
64.92
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, May 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gilead Sciences
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Global Parkinsons Disease Drugs Market Market Development Overview 2021:Johnson & Johnson, Gilead Sciences, Pacira
October 21, 2021
QY Research has made a brilliant attempt to elaborately and meticulously analyze the global Parkinsons Disease Drugs market in its latest report. All of the market forecasts presented in the report are...
Via
SBWire
Topics
Initial Public Offering
Exposures
Securities Market
Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
October 21, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Putting Faith Into Conversations About HIV in the Southern United States
October 19, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
October 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gene Therapy Market Worth $13.0 Billion by 2024 - Exclusive Report by MarketsandMarkets(TM)
October 20, 2021
Chicago, Illinois--(Newsfile Corp. - October 20, 2021) - According to the new market research report "Gene Therapy Market by Vectors...
Via
Newsfile
U.S. Food and Drug Administration Approves Expanded Indication of Gilead’s Biktarvy® for Treatment of HIV-1 in Pediatric Populations
October 18, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Sacituzumab Govitecan Receives Positive CHMP Opinion as 2L Treatment for Adult Patients With Metastatic Triple-Negative Breast Cancer
October 15, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Gilead Sciences to Release Third Quarter 2021 Financial Results on Thursday, October 28, 2021
October 14, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Interns Help Facilitate Breast Cancer Conversations Among Young Black Women
October 12, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead Launches Pharmaceutical Education Program to Increase Workplace Diversity
October 05, 2021
SOURCE: Gilead Sciences
Via
3BL Media
U.S. FDA Approves Kite’s Tecartus® as the First and Only Car T for Adults With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
October 01, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Earlier Use of Yescarta® in Large B-cell Lymphoma
September 30, 2021
From
Kite
Via
Business Wire
Gilead Marks Fifth Approval for Trodelvy® in Metastatic Triple-Negative Breast Cancer Under Project Orbis Initiative with Health Canada Authorization
September 27, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
September 22, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Longwood Fund Announces Longwood Healthcare Leaders, a Virtual Meeting for Industry Leaders on Oct. 4-5, 2021
September 22, 2021
Longwood Fund, an early-stage life science venture firm focused on company creation, will convene several hundred top biotech and pharmaceutical leaders at its fall Longwood Healthcare Leaders meeting,...
Via
Newswire.com
Four Questions With Tracey Iraca: Combating Age-Related Disparities in Blood Cancer Treatment
September 21, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
September 20, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
New Data Demonstrate Trodelvy® Survival Benefit in Metastatic Triple-Negative Breast Cancer Patients Regardless of Initial HR/HER2 Status
September 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Trodelvy® Significantly Improved Quality of Life Over Standard of Care in 2L+ Metastatic Triple-Negative Breast Cancer in Phase 3 ASCENT Study
September 16, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Wake Forest University School of Divinity Brings Faith to the Gilead COMPASS Initiative®
September 15, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Religion
Exposures
Religion
Gilead to Present New Data at ESMO Congress 2021 Reinforcing the Practice-changing Potential of Trodelvy
September 13, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Kay Yow Cancer Fund Works to Bolster Research, Increase Access to Care
September 09, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Death
Exposures
Death
Gilead Sciences to Present at Upcoming Investor Conference
September 01, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
Human Rights Campaign and Gilead Will Work Together to Combat HIV Epidemic and Promote Transgender Justice
August 24, 2021
SOURCE: Gilead Sciences
Via
3BL Media
European Medicines Agency Validates Gilead’s Marketing Authorization Application for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Options
August 19, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
China's Red Ribbon School Provides a Refuge for Children Living With HIV
August 18, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Topics
Bonds
Product Recall
Exposures
Debt Markets
Legal
Product Safety
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
August 11, 2021
SOURCE: Gilead Sciences
Via
3BL Media
Exposures
COVID-19
Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer
August 05, 2021
From
Kite, a Gilead Company
Via
Business Wire
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
August 04, 2021
From
Kite, a Gilead Company
Via
Business Wire
Gilead Sciences Endows Its Foundation With More Than $200 Million to Support Health Justice, Community Giving and Employee Match Program
August 03, 2021
From
Gilead Sciences, Inc.
Via
Business Wire
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.